Tissue factor in infection and severe inflammation

被引:121
作者
Levi, M
van der Poll, T
ten Cate, H
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Expt Med Lab, NL-1105 AZ Amsterdam, Netherlands
[3] Acad Hosp Maastricht, Dept Internal Med, Maastricht, Netherlands
关键词
coagulation; inflammation; infection; tissue factor; mononuclear cells; endothelium;
D O I
10.1055/s-2006-933338
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the pathogenesis of vascular disease, inflammation and coagulation play a pivotal role. Increasing evidence points to an extensive cross-talk between these two systems, whereby inflammation not only leads to activation of coagulation, but coagulation also considerably affects inflammatory activity. Tissue factor (TF) plays an important role at the crossroad of coagulation and inflammation, as the principal initiator of coagulation and an Important modulator of Inflammation. Proinflammatory cytokines can induce TF expression on mononuclear cells and endothelial cells and thereby commence pathways that lead to thrombin generation. Simultaneously, TF may bind to cellular receptors, which may affect the production and release of inflammatory mediators. There is increasing experimental evidence that TF inhibition may have beneficial effects In disease states in which the combination of coagulation and inflammation plays a prominent role.
引用
收藏
页码:33 / 39
页数:7
相关论文
共 59 条
  • [1] Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study
    Abraham, E
    Reinhart, K
    Svoboda, P
    Seibert, A
    Olthoff, D
    Dal Nogare, A
    Postier, R
    Hempelmann, G
    Butler, T
    Martin, E
    Zwingelstein, C
    Percell, S
    Shu, V
    Leighton, A
    Creasey, AA
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (11) : 2081 - 2089
  • [2] Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial
    Abraham, E
    Reinhart, K
    Opal, S
    Demeyer, I
    Doig, C
    Rodriguez, AL
    Beale, R
    Svoboda, P
    Laterre, PF
    Simon, S
    Light, B
    Spapen, H
    Stone, J
    Seibert, A
    Peckelsen, C
    De Deyne, C
    Postier, R
    Pettilä, V
    Sprung, CL
    Artigas, A
    Percell, SR
    Shu, V
    Zwingelstein, C
    Tobias, J
    Poole, L
    Stolzenbach, JC
    Creasey, AA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02): : 238 - 247
  • [3] Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment
    Aird, WC
    Edelberg, JM
    WeilerGuettler, H
    Simmons, WW
    Smith, TW
    Rosenberg, RD
    [J]. JOURNAL OF CELL BIOLOGY, 1997, 138 (05) : 1117 - 1124
  • [4] Vascular bed-specific hemostasis: Role of endothelium in pathogenesis
    Aird, WC
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : S28 - S34
  • [5] AMERI A, 1992, BLOOD, V79, P3219
  • [6] The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor
    Banner, DW
    DArcy, A
    Chene, C
    Winkler, FK
    Guha, A
    Konigsberg, WH
    Nemerson, Y
    Kirchhofer, D
    [J]. NATURE, 1996, 380 (6569) : 41 - 46
  • [7] BAUER KA, 1990, BLOOD, V76, P731
  • [8] BIEMOND BJ, 1995, THROMB HAEMOSTASIS, V73, P223
  • [9] PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 RELEASE DURING EXPERIMENTAL ENDOTOXEMIA IN CHIMPANZEES - EFFECT OF INTERVENTIONS IN THE CYTOKINE AND COAGULATION CASCADES
    BIEMOND, BJ
    LEVI, M
    TENCATE, H
    VANDERPOLL, T
    BULLER, HR
    HACK, CE
    TENCATE, JW
    [J]. CLINICAL SCIENCE, 1995, 88 (05) : 587 - 594
  • [10] TISSUE FACTOR PATHWAY INHIBITOR AND THE REVISED THEORY OF COAGULATION
    BROZE, GJ
    [J]. ANNUAL REVIEW OF MEDICINE, 1995, 46 : 103 - 112